"Attack targets change by cancer type"… AbClon secures Japanese patent for next-generation CAR-T
Predicted impact: Low· Actual: +2.5% vs sector, volume 1.1× normal (5 trading days)
Japanese patent grant for CAR-T technology; no immediate financial effect disclosed.